One of the important achievements in the industrialised countries is the marked reduction in infant mortality. During this century improvement of social and economic circumstances, better hygienic conditions, and methods for the prevention and treatment of most infectious diseases have resulted in an infant mortality as low as 20/1000 live births. In the wealthy countries congenital malformations and genetic diseases have now become the most common cause of infant mortality and morbidity. This is one explanation for the increasing interest in human genetics. Other reasons are the decreasing family size, the increasing independence of women, the availability of new methods of diagnosis and prevention, the ethical aspects involved in some of these, and the increasing costs of optimal medical and social care of the handicapped.
We must, however, be aware of the fact that the importance of early diagnosis and prevention of congenital disease is mainly restricted to the industrialised countries. In the developing countries in Africa, Asia, and Latin America, infant mortality rates are still in the order of 60-120/1000. Here, starvation, vitamin deficiencies, and infectious disease are not only the main causes of death in children but also account for a significant proportion of the overall mortality (Table 1) . Since, by the year 2000, 90% of all children will be born in the developing countries, we probably should be a little more modest about the great importance of the new developments in basic and applied genetics. The overall incidence of congenital disease among liveborn babies varies in different studies but certainly amounts to 4-6/1000 (Stevenson, 1959; Edwards, 1974; Holmes, 1974; Trimble and Doughty, 1974; Carter, 1976; Trimble and Smith, 1977) . The frequency of some major abnormalities in the various categories of congenital disease is summarised in Table 2. I~% 3-5% 2-5% 2-6% 3-4% 50% of the male. Genetic diseases caused by a single gene mutation probably occur in about I % of all newborn infants but each of the 2800 disorders now known to be of mendelian inheritance (McKusick, 1978) is relatively rare. For about 200 of these genetic diseases the responsible molecular defect has been elucidated and about half of the enzyme defects are also expressed in cultured cells from patients (see Stanbury et al., 1978) .
The largest group of congenital disorders are malformations due to abnormal embryonic development, such as spina bifida, anencephaly, congenital heart malformations, and cleft lip/palate (World Health Organisation, 1970; Warkany, 1971; Carter, 1976; Smith, 1976) . Although it is usually assumed that these abnormalities are due to a combination of genetic and exogenous factors, the reality is that we know nothing about their aetiology. In the present lecture I will limit myself to the diagnosis and prevention of genetic metabolic diseases which are based on a single gene mutation because it is in this category only that clinical biochemistry plays an important role.
Approaches to prevention of genetic disease
The main approaches to the prevention of physical and/or metabolic handicaps as a result of genetic disease are:
avoiding harmful environmental factors which increase the mutation frequency; screening all newborn infants for diseases when early treatment can prevent the occurrence of physical and/or mental handicaps; early detection of couples at risk, followed by genetic counselling and preventative measures in case of (subsequent) pregnancy.
REDUCTION OF MUTATION FREQUENCY
Ideally, one would like to avoid the occurrence of deleterious gene mutations, but in practice this is not possible. During evolution innumerable cell divisions have occurred during gametogenesis, and errors in DNA replication unavoidably lead to gene mutations. It is assumed that each individual is heterozygous at about 20 % of all gene loci coding for the structure of enzymes and other proteins (Harris, 1975; Hopkinson, 1976) . Each of us carries several recessive mutations which are lethal in homozygotes, and the chance that two partners carry a similar mutation depends, of course on the frequency of the mutation among the general popuulation. For the most common diseases (for example, cystic fibrosis) the incidence of heterozygotes is 1 in 25-30 but for most other genetic diseases the H. Galjaard heterozygote frequency varies from 1 in 50 to 1 in 150. The risk that two partners carry the same mutation will be greater in consanguinous marriages, and it is therefore important for relatives who intend to marry that proper genetic counselling is obtained.
Several environmental factors are known to increase the mutation frequency, and it is evident that exposure to such factors must be avoided, especially during the reproductive period. During recent years more and more people, politicians, scientists, and workers in various industries, have stressed the need to assess the risks of environmental factors. Of course I agree with this but I also think that many people underestimate the time needed to obtain sufficient data for a good assessment. This is illustrated by the fact that the use of ionising radiation on a larger scale for military purposes and as a source of energy had already started in the I94Os. Since that time much research on the bioligical effects of ionising radiation has been carried out in many centres. all over the world. Yet it has taken more than 30 years before the United Nations Scientific Committee on the Effects of Atomic Radiation could give reasonable estimations of the increase in various categories of congenital diseases as a result of an extra dose of radiation (see UN report, 1977) .
Because of the enormous heterogeneity among the chemical substances to which man is exposed and because of the difficulties of determining the gonadal dose in these instances we should not be too optimistic about the period required to obtain clear answers on chemical mutagenesis. I think that it is a great challenge for biochemists and clinical chemists to develop new methods which allow rapid and large scale testing of mutagenic effects.
NEWBORN SCREENING
New methodology in chemistry has also been an essential step in the early diagnosis of genetic metabolic diseases. After the first application of chromatographic techniques for the detection of metabolites in urine and blood the number of inherited disorders of aminoacid metabolism that has been discovered has increased logarithmically (Scriver and Rosenberg, 1973) . Simplification of some of these methods and the development of rapid microbiological assay systems by Guthrie and co-workers has formed the basis for large-scale newborn screening (see for review: Levy, 1974) . Early detection followed by direct treatment has led to the prevention of physical and/or mental handicaps in some genetic metabolic diseases. The most outspoken example is phenylketonuria (PKU) with an average incidence of 1 in 12000 newborn infants where screening and early treatment have been of great benefit. Some centres, mainly in the United States, have included a large number of other tests in the PKU screening programme, and this has provided new information on the incidence of these diseases and on the relationship between the metabolic defect and the clinical features (see for reviews: Levy, 1974 ; Collaborative Study on the Frequency of Inborn Errors of Metabolism, 1975; National Academy of Sciences USA, Report on Genetic Screening, 1975) . The implications for the treatment of patients however, have remained limited, and thus far only screening for PKU and, more recently, for congenital hypothyroidism has found wide application. The incidence of the latter disorder (1 in 3000--6000 newborn) is high enough and the results of early treatment are good enough to justify nation-wide newborn screening for thyroid (stimulating) hormones (Dussault et al., 1975; Fisher et al., 1976; Report of the European Thyroid Association, 1978) .
HETEROZYGOTE TESTING
The vast majority of genetic diseases cannot be treated, and in these instances efforts can be concentrated only towards the prevention of the birth of affected children. The most effective way would be the identification of heterozygous carriers before reproduction followed by genetic counselling. This approach first requires reliable methods for carrier detection which are applicable on a large scale and at low cost. Secondly, the incidence of heterozygous carriers for the disease concerned must be high enough to justify screening. Thirdly, heterozygous screening must be prepared with much caution as far as the organisational, emotional, and ethical aspects are concerned.
Thus far these conditions have been fulfilled only in the screening of carriers of Tay-Sachs disease among populations of Ashkenazy Jews. Within this ethnic group the I3-N-acetylhexosaminidase A deficiency leading to GM2-ganglioside storage (Tay-Sachs) disease occurs in 1 in 3600 newborns. The incidence of heterozygotes is I in 30 compared with 1 in 300 among other populations. In various areas of the United States, and to a lesser extent in Israel, South Africa, and England, Ashkenazy Jews have been screened for hexosaminidase A activity in their serum and/or leucocytes. At the end of 1976 more than 150000 individuals had been tested and nearly 6700 carriers were identified. Among those were 124 couples who did not yet have any children. These couples at risk were informed about their 25 % risk of getting an affected child and about the possibility of prenatal monitoring and selective abortion in case of pregnancy. By doing so the birth of 12 345 affected children had been prevented at the end of 1976 (see for review : Kaback, 1977) . At the end of 1979 over 250 000 people had been investigated and 210 couples at risk were identified (Kaback et al., 1979) Prevention by heterozygote testing is not feasible for other genetic diseases, either because the responsible molecular defect is not yet known, or because of the lack of a reliable detection method, or because the incidence of the disease is too low. For one of the most common genetic disorders, cystic fibrosis, for example, the responsible biochemical defect has not yet been elucidated and none of the methods proposed for carrier detection is sufficiently reliable. For other diseases, suitable methodology is available, but the incidence is so low that 10000 tests would be required to prevent the birth of one affected child (Motulsky et al., 1971) .
My personal opinion is that, instead of investing money in screening for very rare genetic diseases, it is more fruitful to use the limited funds for basic research on the responsible molecular defects in more frequent genetic diseases associated with severe handicaps. This type of work is one of the challenges in biochemistry. Other people might disagree with me and will argue that a favourable cost-benefit analysis is sufficient to justify screening for heterozygotes or for patients with a disease that can be treated.
EARLY DIAGNOSIS AND GENETIC COUNSELLING
In most instances, the diagnosis of a genetic disease in one of the children will be the first signal to parents that both are carriers of the same deleterious recessive gene mutation. Efforts must then be made to avoid recurrence in subsequent pregnancies. This requires early diagnosis of each of the 2800 different genetic diseases now known to be due to a single gene mutation. The impressive heterogeneity in clinical features among the various diseases, the fact that most of them are rare, and the necessity of interdisciplinary collaboration are all factors that complicate early diagnosis. Yet it is very important to aim for an early and exact diagnosis of genetic diseases because it has been shown in several followup studies that the reproductive behaviour of couples at risk is markedly influenced by information given to them during genetic counselling. A couple at risk for a child with a recessive or dominant inherited disease has the following alternatives: no (further) pregnancies and consideration of adoption; accept a 25 % or 50 % risk of an affected child with the hope that a normal child will be born;
artificial insemination with donor sperm in case the man is carrier of a dominant mutation or of the same recessive mutation as his wife; prenatal monitoring for those genetic diseases that can be demonstrated by analysis of amniotic fluid cells; when the fetus is found to be affected parents may ask for interruption of their pregnancy, thus avoiding the birth of a handicapped child.
It is clear that the decisions that have to be made by parents at risk are difficult and of a highly emotional nature. Genetic counselling must therefore be based on exact data about the (molecular) diagnosis of the disease and its pattern of inheritance. There must be sufficient time available to discuss the various alternatives with the parents in different sessions. Finally, the experts involved in the diagnosis and counselling should not stress their own opinions but instead they must help the people at risk to make their own decisions. Several studies have indicated that 50-SO % of couples at high risk are deterred from (further) pregnancy on the basis of information given during genetic counselling (Carter et al., 1971; Leonard et al., 1972; Clow et al., 1973; Reynolds et al., 1974; Briard et al., 1977; Klein and Weyss, 1977) . The decision not to have any (further) children is very difficult indeed, and for many couples at risk the possibility of prenatal monitoring offers new perspectives. This is especially true for parents who have (lost) one or more affected children and who do not have any healthy offspring. In the following section some major aspects of early diagnosis and prenatal analysis of genetic metabolic diseases will be summarised.
Early diagnosis of genetic metabolic disease
During a very long period diagnosis and classification of diseases was the exclusive task of clinicians. Many of the syndromes, now known to be genetic metabolic diseases, are still named after the clinicians who first discovered the unique combination of clinical features. Later on, the contribution of pathologists led to the description of morphological lesions and initiated the identification of specific stored products in certain diseases. During the last 50 years, biochemistry has played an increasingly important role in the elucidation of metabolic derangements in genetic diseases. The accumulation or lack of specific metabolites usually formed the basis for the exact identification of the responsible defect of an enzyme or other protein. At present the molecular defect is known in nearly 200 different genetic diseases. The diagnosis in those diseases must be based on the demonstration of the responsible protein defect. In several instances it is also possible to find a partial protein defect, mostly a decreased activity of a particular enzyme, in heterozygotes. In such cases mendelian inheritance of a disease can be demonstrated by biochemical analyses of cell material from a few family members only.
For the majority of genetic diseases the responsible molecular defect is not yet known, and consequently the diagnosis can be based only on clinical and pathological manifestations whereas the pattern of inheritance has to be established by extensive pedigree studies.
It is clear that the early diagnosis of many genetic diseases requires the collaboration of several disciplines and experts. Often the patient and sometimes other relatives have to be examined by various clinicians, the pathologist, clinical chemist, protein chemist, psychologist, and geneticist before final conclusions can be reached about the diagnosis, prognosis, and recurrence risk. A real danger of this example of modern medical care is that none of the specialists feels responsible for the overall situation of the patient and family and that the parents of the retarded child feel lost among all the experts.
In the near future I expect that still another approach will be added to the early and exact diagnosis of genetic disease. This is the demonstration of a genetic defect at the level of the genome itself. During the last decade it has become apparent for an increasing number of diseases that a 'similar' deficiency of an enzyme or other protein can be associated with very different clinical features. progressive infantile forms, late onset, and less progressive, juvenile forms and even adult, mild forms have been discovered within the 'same' genetic disease. Sometimes this clinical heterogeneity is associated with differences in the biochemical characteristics of the molecular defect but often this is not the case. One means of discovering whether or not different gene mutations are involved in different clinical forms of 'the same' enzyme deficiency is complementation analysis after somatic cell hybridisation (Fig. 1) . Cultured skin fibroblasts from two different patients, both with a similar enzyme deficiency, are hybridised using Sandai virus or polyethylene glycol and, after a few days of in vitro cultivation, enzyme assays are carried out to measure whether or not restoration of enzyme activity has occurred in heterokaryons. Such complementation analyses can either be performed on an homogenate from a mixed population offused and non-fused cells from both patients, or ultramicrochemical enzyme assays can be carried out on single binuclear cells, half of which are heterokaryons containing the genome from both mutant fibroblasts. If restoration of enzyme activity occurs after hybridisation this Fig. 1 Schematic illustration of the procedure to investigate whether 'the same' enzyme deficiency in fibroblasts from two different types ofpatients is based Oil different gene mutations, using somatic cell hybridisation.
proves that the different clinical features associated with 'the same' enzyme defect are due to different gene mutations. Using p-galactosidase assays of single binuclear cells we have, for instance, been able to show complementation after fusion of two cell strains with a p-galactosidase deficiency derived from a patient with the infantile, progressive form of GM1-gangliosidosis and from an adult patient with milder clinical features (GaIjaard et al., 1975) . Hybridisation studies have so far contributed to our insight into the genetic background of several other metabolic diseases (for reviews, GaIjaard and Reuser, 1977; Bootsma and Galjaard, 1979) . It has been demonstrated that different gene mutations are involved in clinical variants of GM1-and G M2gangliosidoses, Niemann-Pick disease (sphingomyelinase deficiency), various sialidoses (neuraminidase deficiency), xeroderma pigmentosum (DNArepair defect), and the aminoacidopathies methylmalonicaciduria and maple syrup urine disease.
It may well be that in the future certain types of gene mutations can be related with certain combinations of clinical features. Fusion of cells from a newborn with a particular genetic enzyme defect with fibroblasts from patients with a known clinical course of the disease may then be of prognostic value. Another issue is that such early information about the future development of severe physical and mental handicaps and the possible life expectancy of a patient will raise ethical problems.
Another promising approach to the diagnosis at the level of the genome is the use of restriction enzymes and molecular hybridisation with radioactive complementary DNA. Recently, this method has been successfully applied in the demonstration of gene mutations that are responsible for the haemoglobinapathies, p-thalassemia (Orkin et al., 1978) and sickle-cell anaemia (Kan and Dozy, 1978) . Direct analyses of DNA mutations have the great advantage that it is no longer necessary for a particular protein defect to be expressed in the cell material that is being analysed.
Although the investigation of gene mutations in relation to metabolic diseases is still in the early phase of research it is likely that the clinical chemist will become involved in this diagnostic approach as soon as the methodology is simplified and more widely applicable.
Early diagnosis of genetic disease will then involve the sequence: recognition by parents, general practitioner, paediatrician, and/or psychologist that something is wrong with the development of a child; extensive clinical investigation, sometimes supplemented with pathological examination of cell or tissue material; clinical chemistry of blood, urine, and other body fluids aiming for the demonstration of changes in quantity and/or quality of specific metabolites; protein chemistry to identify a genetic deficiency of a specific enzyme or other protein, using biochemical assays on organ biopsies, blood cells, and/ or cultured skin fibroblasts.
analysis of the exact type of gene mutation using methods developed in somatic cell genetics and nucleic acid research.
Prenatal analysis of genetic metabolic disease
Since the first report on biochemical analyses of cultured amniotic fluid cells (Nadler, 1968) it has been demonstrated that prenatal monitoring is feasible for about 75 different genetic metabolic diseases (see, for recent reviews, Nadler, 1977; Galjaard, 1979a,b) . So far, practical experience has been obtained with the prenatal diagnosis of 35 differentmetabolicdefects (Galjaard, 1976 (Galjaard, , 1979 (Galjaard, , 1980 Epstein and Golbus, 1977) . From the largest published series it appears that about 20000 pregnancies at risk have been monitored for chromosomal aberrations, neutral tube defects, and genetic metabolic diseases (Table 3 ). The last category forms a minority and accounts for about 5~~of all cases of prenatal analyses in the 15-16th week of pregnancy.
At the request of the organisers of the Third European Conference on Prenatal Diagnosis in 1978, I have collected data of all prenatal analyses for metabolic diseases made in Western Europe and Israel. The results of this survey, illustrated in Table  4 , indicate that relatively few prenatal analyses have been performed for aminoacidopathies. This might be related to the fact that some of these diseases have a rapid fatal course and that patients die before a diagnosis has been made. It is therefore very important that from each baby with a severe condition that might be due to a genetic disease, samples of urine and blood and a skin biopsy are taken to allow extensive biochemical diagnostic analyses even after the baby might have died. This is essential for proper genetic counselling and to allow prenatal analyses in subsequent pregnancies.
As can be seen from Table 4 , the largest number of prenatal analyses concern inborn errors in the metabolism of lipids and mucopolysaccharides. The overall percentage of fetuses that was found to be affected is 23~~, which is very close to the theoretical value of the 25 % recurrence risk expected for diseases of mendelian recessive inheritance. This good agreement points to the reliability of prenatal monitoring. In various studies it has been shown conclusively that transabdominal amniocentesis in the 15-16th week of pregnancy carries very little risk for mother and fetus (Galjaard, 1976; National Institute of Child Health Study, 1976; Golbus et al., 1979; Murken et al., 1979) provided that it is carried out under proper conditions and by experienced obstetricians. When conventional analytical techniques are being used for the demonstration of an enzyme deficiency in cultured amniotic fluid cells, at least 1-10 mg of cellular protein is required. This corresponds to 3 x 10 6 to 3 x 10 7 cultured cells, which numbers are usually obtained after four to six weeks cultivation of the few viable fetal cells in an amniotic fluid sample of 10-20 ml. For the parents at risk this long waiting period often means a heavy psychological burden and we have therefore developed more sensitive ultramicrochemical techniques which permit analyses of small numbers of cultured cells and hence a reduction of the cultivation period. The principles of the preparation procedure. incubation in (sub)microlitre volumes and extinction and fluorescence measurements using a microscope spectrofluorometer (Fig. 2) . have been derived mainly from work in quantitative histochemistry by the groups of Lowry, Glick, and Caspersson.
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To isolate small numbers (dozens to a few hundred) or even single cultured cells. we cultivate amniotic fluid cells and fibroblasts in dishes with a bottom of thin plastic foil. When clones of sufficient size have grown the whole dish is quickly frozen and freeze-dried and a counted number of lyophilised cells can be isolated by free-hand dissection of small pieces of the plastic foil using a stereomicroscope. These are incubated in (sub)microlitre volumes of substrate which are covered by paraffin oil to prevent evaporation. Homogenisation of the freezedried cells is not necessary since model experiments have shown that both cytoplasmic and research in somatic cell genetics and cell differentiation during early embryonic development. The complementation studies in individual heterokaryons after cell hybridisation, mentioned in the previous paragraph (Figs 1-2 ), are only one example of the possi bilities of microchemical analyses of single cells. Some future developments in the prenatal diagnosis of metabolic diseases are the analyses of fetal blood (cells), investigation of fetal lymphocytes in the maternal circulation, and the demonstration of genetic defects at hte level of DNA. The obstetrical methods for fetal blood sampling in the 16-18th week of pregnancy, although still in an experimental stage, do improve and are presently used mainly for the prenatal monitoring of haemoglobinopathies (Golbus et al., 1976; Leonard and Kazazian, 1978; Rodeck et al., 1979) . Once fetal blood sampling is Disrase membrane-bound enzymes are liberated (for reviews see Galjaard, 1979 Galjaard, , 1980 . Extinction measurements can ce performed in microcuvettes down to 20-40 III in a normal spectrophotometer and in 1 III volumes using microcapillaries and a microscope spectrophotcmeter. The latter measurements in l mrn-' droplets have the disadvantage of a 1mm optical path instead of the normal l Omm length, but this is compensated for by the fact that in microscope spectrophotometry about 10 times lower extinction values can be measured reliably (for review, see . Recently, de Josselin de long et al., in our department have designed a colorimeter which combines the advantages of rapid and easy change of cuvettes with a 10mrn optical path and those of good optics and exact positioning of light beam and cuvettes under microscopic control. This instrument allows rapid and reliable extinction measurements in volumes ranging from 5 III to 3 ml. Fluorescence measurements can be performed at high sensitivity using microdroplets (0'05 III to 1 Ill) and a microscope fluorometer. We found the inverted microscope fluorometer with epi-illumination (longkind et al., 1974) most easy to handle. By combining incubation volumes in the order of 0·05-0·2 III (to reduce blank values) and measurements in droplets after dilution to 1-2 III final volume methylumbelliferone can be detected in amounts as low as 10-1 4 moles. Since the activities of many enzymes involved in inborn errors of carbohydrate, mucopolysaccharide, and lipid metabolism are in the order of 10-1 3_10-1 5 mol/hr per cell prenatal analyses for these diseases can be performed on dozens to a few hundred cultured amniotic fluid cells (Table 5 ). These microtechniques enable prenatal diagnoses to be established within seven to 14 days after amniocentesis Kleijer et al., 1978; Galjaard, 1979 Galjaard, ,1980 . Several investigators have also attempted to increase the sensitivity of radiometric techniques. Wendel et al., (1973) have reported a microassay for the analysis of ketoacid decarboxylase activity, which is based on incubation of living cultured cells in the wells of a microtitreplate containing medium with radioactive substrate, followed by trapping 14C02, which is then measured by scintillation counting. This approach could be more widely used. The same is true for the chromatographic procedure to assay cystine accumulation in 10 4 cultured cells described by Willcox and Patrick (1974) . It is to be expected that in future years more and more attention will be paid to the development of ultramicrochemical methods both for the purpose of early diagnosis and screening and for fundamental a routine, with sufficient safety for mother and fetus, it could also be used as a general technique for the monitoring of genetic metabolic diseases. In our department, we have shown that genetic enzyme deficiencies, which can be demonstrated in leucocytes from patients, are also expressed in fetal white blood cells as early as the 16-18th week of pregnancy (Galjaard, 1980) . Fetal blood sampling followed by microchemical assay of the collected fetal leucocytes would enable prenatal diagnosis to be established within one to two days. Microtechniques would also be useful in collecting fetal lymphocytes from the maternal circulation with the fluorescence activated cell sorter described by Herzenberg et al., (l979) .
If this approach turned out to be more generally applicable, amniocentesis would no longer be required.
The method of demonstrating gene mutations at the level of DNA by using restriction enzymes and molecular hybridisation has already been applied to a few uncultured amniotic fluid cells for the prenatal diagnosis of sickle-cell anaemia (Kan and Dozy, 1978) . The great advantage of this approach is that the scope of prenatal diagnosis can also be widened to diseases in which the metabolic defect is not expressed in cultured amniotic fluid cells.
Although it is necessary and stimulating to work on new methods which might improve early diagnosis, treatment, and prevention of genetic disease, we must not forget to ask whether existing methods are available for those who are in need of them. In my opinion, this is not the case. An official inventory some years ago in my own country showed that only 20-25 % of all patients with a chromosomal disorder or genetic disease had been examined by the proper methods. Only 7-10% of patients at risk for a congenital disorder had received proper genetic counselling, and at present 50-60 % of all pregnant women who should undergo amniocentesis are referred to clinics for prenatal monitoring. If we know that more than 50% of patients in institutions for the mentally handicapped are undiagnosed, it must be clear to everybody that there is still much work to be done before all existing methods of diagnosis and prevention are optimally applied.
We will be able to achieve this goal only if the clinicians spend more time listening to parents and patients and if they accept more easily that another colleague might know more. The laboratory worker, including the clinical chemist, must be careful not to be completely absorbed by the increasing number and complexity of laboratory instruments; there is a great danger that the needs of the individual patient, or an unexpected result which might lead to new discoveries, may no longer be recognised.
Finally, I think that we can make real progress only if experts in different disciplines try harder to give understandable information to the general public about the meaning of their activities.
